Efficacy of cytokine‑induced killer cells targeting CD40 and GITR

Biederbick,Kaja  D.; Schmidt‑Wolf,Ingo  G.H.

doi:10.3892/ol.2018.9849

Efficacy of cytokine‑induced killer cells targeting CD40 and GITR

Authors:
- Kaja D. Biederbick
- Ingo G.H. Schmidt‑Wolf
View Affiliations

Affiliations: Department of Internal Medicine III, University Hospital Bonn, D‑53105 Bonn, Germany, Department of Integrated Oncology, CIO Bonn, University Hospital Bonn, D‑53105 Bonn, Germany
Published online on: December 18, 2018 https://doi.org/10.3892/ol.2018.9849
Pages: 2425-2430

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Since the publication of a novel protocol in 1991, cytokine‑induced killer (CIK) cells have shown promising results in the treatment against neoplastic diseases. Despite ongoing preclinical and clinical studies, CIK cell treatment in the context of human monoclonal antibodies targeting tumor‑necrosis factor receptors remains overlooked. The present study investigated whether a combination of CIK cells with human monoclonal antibody anti‑CD40 and anti‑Glucocorticoid‑induced TNF‑related protein (GITR) would lead to further cytotoxicity against tumor cells expressing CD40 and GITR ligand (L). Therefore, in vitro experiments with human lymphoma cell lines SU‑DHL‑4 and Daudi (both CD40 positive) and human breast adenocarcinoma MCF‑7 (GITRL positive) were performed and the secretion of interferon (IFN)‑γ was measured. Three interesting results emerged: i) a combination of CIK cells and anti‑CD40 mAb is more effective than CIK cell treatment alone; ii) the use of anti‑GITR mAb and CIK cells significantly enhanced the cytotoxicity of CIK cells against MCF‑7 compared with single CIK cell treatment and iii) the combination of both antibodies and CIK cells abrogates the anti tumoral effect of CIK cells on all three cell lines. By performing an ELISA for IFN‑γ measurement, a lower secretion was observed when anti‑CD40 or anti‑GITR mAb was added. This outcome indicates that further studies in vitro and in vivo may aid in understanding the synergistic molecular mechanisms of CIK cells, and anti‑CD40 and anti‑GITR mAb.

View Figures

View References

1	Bishop GA: The multifaceted roles of TRAFs in the regulation of B-cell function. Nat Rev Immunol. 4:775–786. 2004. View Article : Google Scholar : PubMed/NCBI
2	Pellat-Deceunynck C, Bataille R, Robillard N, Harousseau JL, Rapp MJ, Juge-Morineau N, Wijdenes J and Amiot M: Expression of CD28 and CD40 in human myeloma cells: A comparative study with normal plasma cells. Blood. 84:2597–2603. 1994.PubMed/NCBI
3	Westendorf JJ, Ahmann GJ, Armitage RJ, Spriggs MK, Lust JA, Greipp PR, Katzmann JA and Jelinek DF: CD40 expression in malignant plasma cells. Role in stimulation of autocrine IL-6 secretion by a human myeloma cell line. J Immunol. 152:117–128. 1994.PubMed/NCBI
4	Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S and Ledbetter JA: Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood. 76:2449–2456. 1990.PubMed/NCBI
5	O'Grady JT, Stewart S, Lowrey J, Howie SE and Krajewski AS: CD40 expression in Hodgkin's disease. Am J Pathol. 144:21–26. 1994.PubMed/NCBI
6	van Kooten C and Banchereau J: CD40-CD40 ligand. J Leukoc Biol. 67:2–17. 2000. View Article : Google Scholar : PubMed/NCBI
7	Banchereau J, Bazan F, Blanchard D, Brière F, Galizzi JP, van Kooten C, Liu YJ, Rousset F and Saeland S: The CD40 antigen and its ligand. Annu Rev Immunol. 12:881–922. 1994. View Article : Google Scholar : PubMed/NCBI
8	Law CL, Gordon KA, Collier J, Klussman K, McEarchern JA, Cerveny CG, Mixan BJ, Lee WP, Lin Z, Valdez P, et al: Preclinical antilymphoma activity of a humanized anti-CD40 monoclonal antibody, SGN-40. Cancer Res. 65:8331–8338. 2005. View Article : Google Scholar : PubMed/NCBI
9	Costello RT, Gastaut JA and Olive D: What is the real role of CD40 in cancer immunotherapy? Immunol Today. 20:488–493. 1999. View Article : Google Scholar : PubMed/NCBI
10	Baltz KM, Krusch M, Bringmann A, Brossart P, Mayer F, Kloss M, Baessler T, Kumbier I, Peterfi A, Kupka S, et al: Cancer immunoediting by GITR (glucocorticoid-induced TNF-related protein) ligand in humans: NK cell/tumor cell interactions. FASEB J. 21:2442–2454. 2007. View Article : Google Scholar : PubMed/NCBI
11	Baessler T, Krusch M, Schmiedel BJ, Kloss M, Baltz KM, Wacker A, Schmetzer HM and Salih HR: Glucocorticoid-induced tumor necrosis factor receptor-related protein ligand subverts immunosurveillance of acute myeloid leukemia in humans. Cancer Res. 69:1037–1045. 2009. View Article : Google Scholar : PubMed/NCBI
12	Buechele C, Baessler T, Wirths S, Schmohl JU, Schmiedel BJ and Salih HR: Glucocorticoid-induced TNFR-related protein (GITR) ligand modulates cytokine release and NK cell reactivity in chronic lymphocytic leukemia (CLL). Leukemia. 26:991–1000. 2012. View Article : Google Scholar : PubMed/NCBI
13	Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG, Weissman IL and Negrin RS: Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol. 21:1673–1679. 1993.PubMed/NCBI
14	Nwangwu CA, Weiher H and Schmidt-Wolf IGH: Increase of CIK cell efficacy by upregulating cell surface MICA and inhibition of NKG2D ligand shedding in multiple myeloma. Hematol Oncol. 35:2016.PubMed/NCBI
15	He JY, Jia ZX, Cai XH, Han WM, Xiao R, Ma LD, Lu XZ, Zhou M and Chen BA: Roles of NKG2D in cytokine-induced killer (CIK) against hematological malignant cells lines. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 21:1380–1384. 2013.(In Chinese). PubMed/NCBI
16	Verneris MR, Karimi M, Baker J, Jayaswal A and Negrin RS: Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells. Blood. 103:3065–3072. 2004. View Article : Google Scholar : PubMed/NCBI
17	Zhao H, Fan Y, Li H, Yu J, Liu L, Cao S, Ren B, Yan F and Ren X: Immunotherapy with cytokine-induced killer cells as an adjuvant treatment for advanced gastric carcinoma: A retrospective study of 165 patients. Cancer Biother Radiopharm. 28:303–309. 2013. View Article : Google Scholar : PubMed/NCBI
18	Hao MZ, Lin HL, Chen Q, Ye YB, Chen QZ and Chen MS: Efficacy of transcatheter arterial chemoembolization combined with cytokine-induced killer cell therapy on hepatocellular carcinoma: A comparative study. Chin J Cancer. 29:172–177. 2010. View Article : Google Scholar : PubMed/NCBI
19	Yang B, Lu XC, Yu RL, Chi XH, Liu Y, Wang Y, Dai HR, Zhu HL, Cai LL and Han WD: Repeated transfusions of autologous cytokine-induced killer cells for treatment of haematological malignancies in elderly patients: A pilot clinical trial. Hematol Oncol. 30:115–122. 2012. View Article : Google Scholar : PubMed/NCBI
20	Schmeel LC, Schmeel FC, Coch C and Schmidt-Wolf IG: Cytokine-induced killer (CIK) cells in cancer immunotherapy: Report of the international registry on CIK cells (IRCC). J Cancer Res Clin Oncol. 141:839–849. 2015. View Article : Google Scholar : PubMed/NCBI
21	Wang Y, Xu Z, Zhou F, Sun Y, Chen J, Li L, Jin H and Qian Q: The combination of dendritic cells-cytotoxic T lymphocytes/cytokine-induced killer (DC-CTL/CIK) therapy exerts immune and clinical responses in patients with malignant tumors. Exp Hematol Oncol. 4:322015. View Article : Google Scholar : PubMed/NCBI
22	Wang Z, Liu Y, Li R, Shang Y, Zhang Y, Zhao L, Li W, Yang Y, Zhang X, Yang T, et al: Autologous cytokine-induced killer cell transfusion increases overall survival in advanced pancreatic cancer. J Hematol Oncol. 9:62016. View Article : Google Scholar : PubMed/NCBI
23	Jäkel CE and Schmidt-Wolf IG: An update on new adoptive immunotherapy strategies for solid tumors with cytokine-induced killer cells. Expert Opin Biol Ther. 14:905–916. 2014. View Article : Google Scholar : PubMed/NCBI
24	Jäkel CE, Vogt A, Gonzalez-Carmona MA and Schmidt-Wolf IG: Clinical studies applying cytokine-induced killer cells for the treatment of gastrointestinal tumors. J Immunol Res. 2014:8972142014. View Article : Google Scholar : PubMed/NCBI
25	Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG and Weissman IL: Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 174:139–149. 1991. View Article : Google Scholar : PubMed/NCBI
26	Cappuzzello E, Tosi A, Zanovello P, Sommaggio R and Rosato A: Retargeting cytokine-induced killer cell activity by CD16 engagement with clinical-grade antibodies. Oncoimmunology. 5:e11993112016. View Article : Google Scholar : PubMed/NCBI
27	Hassan SB, Sørensen JF, Olsen BN and Pedersen AE: Anti-CD40-mediated cancer immunotherapy: An update of recent and ongoing clinical trials. Immunopharmacol Immunotoxicol. 36:96–104. 2014. View Article : Google Scholar : PubMed/NCBI
28	Szocinski JL, Khaled AR, Hixon J, Halverson D, Funakoshi S, Fanslow WC, Boyd A, Taub DD, Durum SK, Siegall CB, et al: Activation-induced cell death of aggressive histology lymphomas by CD40 stimulation: Induction of bax. Blood. 100:217–223. 2002. View Article : Google Scholar : PubMed/NCBI
29	Brady HJM and Gil-Gómez G: Molecules in focus Bax. The pro-apoptotic Bcl-2 family member, Bax. Int J Bio Cell Biol. 30:647–650. 1998. View Article : Google Scholar
30	Martin S, Pahari S, Sudan R and Saha B: CD40 signaling in CD8+CD40+ T cells turns on contra-T regulatory cell functions. J Immunol. 184:5510–5518. 2010. View Article : Google Scholar : PubMed/NCBI
31	McWhirter SM, Pullen SS, Holton JM, Crute JJ, Kehry MR and Alber T: Crystallographic analysis of CD40 recognition and signaling by human TRAF2. Proc Natl Acad Sci USA. 96:8408–8413. 1999. View Article : Google Scholar : PubMed/NCBI
32	Tsukamoto N, Kobayashi N, Azuma S, Yamamoto T and Inoue J: Two differently regulated nuclear factor kappaB activation pathways triggered by the cytoplasmic tail of CD40. Proc Natl Acad Sci USA. 96:1234–1239. 1999. View Article : Google Scholar : PubMed/NCBI
33	Esparza EM and Arch RH: Glucocorticoid-induced TNF receptor, a costimulatory receptor on naive and activated T cells, uses TNF receptor-associated factor 2 in a novel fashion as an inhibitor of NF-kappa B activation. J Immunol. 174:7875–7882. 2005. View Article : Google Scholar : PubMed/NCBI
34	Melero I, Grimaldi AM, Perez-Gracia JL and Ascierto PA: Clinical development of immunostimulatory monoclonal antibodies and opportunities for combination. Clin Cancer Res. 19:997–1008. 2013. View Article : Google Scholar : PubMed/NCBI
35	Zhu BQ, Ju SW and Shu YQ: CD137 enhances cytotoxicity of CD3(+)CD56(+) cells and their capacities to induce CD4(+) Th1 responses. Biomed Pharmacother. 63:509–516. 2009. View Article : Google Scholar : PubMed/NCBI
36	Esser L, Weiher H and Schmidt-Wolf I: Increased efficacy of brentuximab vedotin (SGN-35) in combination with cytokine-induced killer cells in lymphoma. Int J Mol Sci. 17(pii): E10562016. View Article : Google Scholar : PubMed/NCBI